Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ISOBIOTICS

Financiado

Isotopic Labeling of Biotherapeutics

Biological drugs such as peptides, proteins, oligonucleotides and analogs provide the patients with more efficacious and less toxic treatments and have lower attrition rates than chemical drugs since 1 on 9 new biological entities... ver más

31/01/2027

CEA

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 17 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-07-14

HORIZON-MSCA-2021-DN-01-01: MSCA Doctoral Networks 2021 ExpectedOutcome:

I+D

Cerrada hace 3 años

0% 100% 100%

17 Participantes

CEA

848.08K€ | Lider

N.D. | Participante

LMU MUENCHEN

260.54K€ | Participante

ASTRAZENECA UK LIMITED

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2021-128948OB-I00 DESARROLLO DE NUEVOS METODOS DE MODIFICACION SINTETICA DE AN... 182K€ Cerrado

MAT2012-38573-C02-01 PLATAFORMAS DE DIAGNOSTICO UNIVERSAL BASADAS EN NANOPARTICUL... 121K€ Cerrado

SAF2014-54057-R DESARROLLO DE NANOMEDICINAS PARA TERAPIAS ANTITUMORALES E IN... 242K€ Cerrado

CTQ2016-77978-R MEJORANDO LA SELECTIVIDAD EN TERANOSTICA Y EN PROCESOS QUIMI... 105K€ Cerrado

COBIOE GROWING CONNECTION FOR BIO ECOSYSTEMS 500K€ Cerrado

PID2021-128057NB-I00 RECEPTORES SINTETICOS QUIRALES PARA MOLECULAS BIOLOGICAMENTE... 115K€ Cerrado

Duración del proyecto: 54 meses Fecha Inicio: 2022-07-14
Fecha Fin: 2027-01-31

Líder del proyecto

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Descripción del proyecto Biological drugs such as peptides, proteins, oligonucleotides and analogs provide the patients with more efficacious and less toxic treatments and have lower attrition rates than chemical drugs since 1 on 9 new biological entities entering clinical trials reaches the market (1 on 16 for chemical drugs). Consequently, 15 on 24 top blockbuster drugs were biotherapeutics in 2020 (world-market share of about 40% of $175 billion of revenue per year). In order to reduce the immunogenicity of biodrugs, to overcome their fragility and to increase their capacity to reach quickly and massively their target, reduced-size biologics are extensively developed. However, radiolabeling of large molecules by grafting bifunctional chelating agents which do not alter significantly their biological activity is thus no longer possible with smaller biodrugs. It is therefore of paramount importance to devise new radiolabeling approaches carried out on tiny quantities in aqueous media and very soft conditions. It is also crucial to train a new generation of radiochemists in order to implement these methods and to meet the needs of the European industry. ISOBIOTICS ambitions: 1) to develop new chemically-benign strategies for the last-stage radiolabeling of large peptides, small/medium-size proteins, oligonucleotides and analogs with deuterium, tritium and carbon-14 (preclinical and phase 0 clinical evaluation), and fluorine-18 (phase I-III clinical trials); 2) to educate a new generation of young talented PhD students specialized in the radiolabeling of biologics through a combination of interdisciplinary lab research, transdisciplinary and intersectorial secondments, technical taught courses, scientific lectures and complementary skills workshops; 3) to ensure the appropriate dissemination, exploitation and communication of all ISOBIOTICS outputs in order to maximize the project’s impact and radiance; 4) to secure the students employment and the sustainability of training structures.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores